Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 13/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63038 | 0.89 | HPGDS (0.51) | HPGDSPRKAA2HRH3SMYD3FLT3 | |
| SCHEMBL5020462 | 0.86 | GPR119 (0.50) | HPGDSPRKAA2 | |
| SCHEMBL5020461 | 0.83 | PRKAA2 (0.59) | PRKAA2 | |
| SCHEMBL12199810 | 0.81 | FLT3 (0.41) | HPGDSPRKAA2HRH3SMYD3FLT3 | |
| SCHEMBL14649234 | 0.81 | MAOB (0.52) | HPGDSPRKAA2SMYD3FLT3AR | |
| SCHEMBL91106 | 0.81 | HRH3 (0.51) | HPGDSPRKAA2HRH3 | |
| SCHEMBL2696228 | 0.80 | HPGDS (0.46) | HPGDSPRKAA2HRH3 | |
| SCHEMBL13809383 | 0.79 | SCN9A (0.42) | HPGDSPRKAA2AR | |
| SCHEMBL4405686 | 0.79 | MAOB (0.43) | HRH3SMYD3AR | |
| SCHEMBL4405713 | 0.79 | UTS2R (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895578-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8557822-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | HPGDS 3138/4885PRKAA2 3/4885HRH3 2573/4885 |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | HPGDS 3138/4885PRKAA2 3/4885HRH3 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.